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OBJECTIVES The purpose of this study was to determine the incidence of bleeding, vascular, and ischemic
complications using three different heparin regimens after successful intervention.
BACKGROUND The ideal dose and duration of heparin infusion after successful coronary intervention is
unknown.
METHODS Patients were randomized to one of three heparin strategies after coronary intervention:
Group 1 (n 5 157 patients) received prolonged (12 to 24 h) heparin infusion followed by
sheath removal; Group 2 (n 5 120 patients) underwent early removal of sheaths, followed by
reinstitution of heparin infusion for 12 to 18 h; Group 3 (n 5 137 patients) did not receive
any further heparin after intervention with early sheath removal. The primary end point of the
study was the combined incidence of in-hospital bleeding and vascular events. Secondary end
points included in-hospital ischemic events, length of stay, cost and one-month outcome.
RESULTS After successful coronary intervention, 414 patients were randomized. Unstable angina or
postinfarction angina was present in 83% of patients before intervention. The combined
incidence of bleeding and vascular events was 21% in Group 1, 14% in Group 2 and 8% in
Group 3 (p 5 0.01). The overall incidence of in-hospital ischemic complications was 2.2%;
there were no differences between groups. Length of hospital stay was shorter (p 5 0.033) and
adjusted hospital cost was lower (p , 0.001) for Group 3. At 30 days, the incidence of delayed
cardiac and vascular events was similar for all three groups.
CONCLUSIONS Heparin infusion after successful coronary intervention is associated with more minor
bleeding and vascular injury, prolonged length of stay and increased cost. In-hospital and
one-month ischemic events rarely occur after successful intervention, irrespective of heparin
use. Routine postprocedure heparin is not recommended, even in patients who present with
unstable ischemic syndromes. (J Am Coll Cardiol 1999;34:461–7) © 1999 by the American
College of Cardiology
Before percutaneous coronary intervention, aspirin and
heparin are routinely administered to reduce the risk of
vessel occlusion (1–18). Despite widespread use of percuta-
neous transluminal coronary angioplasty (PTCA) for nearly
20 years, the ideal doses of both intra- and postprocedural
heparin are unknown (1). A recent national survey on
anticoagulation for PTCA reported the routine use of post-
procedural heparin in 70% of procedures (9). Furthermore,
although heparin is clearly indicated during the interventional
procedure, the need for any postprocedural heparin has not
been clearly established. Despite the results of a recent ran-
domized trial (10), which demonstrated that, for elective
PTCA and a good angiographic result, no further postproce-
dural heparin was necessary and early discharge was safe, this
strategy has not been widely applied to patients with unstable
ischemic syndromes because of concerns of postprocedural
ischemic complications. Accordingly, the purpose of this study
was to determine the incidence of bleeding, vascular and
ischemic complications associated with three different postpro-
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cedural heparin strategies in patients with stable and unstable
ischemic syndromes.
METHODS
Patient population. Between May 1995 and June 1996, a
total of 414 patients from six institutions were enrolled in
this prospective randomized trial. Written informed consent
was obtained from each patient according to protocols
approved by the Human Studies Committee at each insti-
tution. All patients received aspirin (325 mg daily) at least
24 h before intervention. Patients were considered for
enrollment in the study after successful balloon angioplasty,
laser or atherectomy of a native coronary artery. Success was
defined as final diameter stenosis ,35% without flow-
limiting dissection, using on-line visual estimates of stenosis
severity. Patients with cardiogenic shock, myocardial infarc-
tion within five days, intracoronary stent implantation and
need for chronic warfarin anticoagulation were excluded.
Heparin administration. After insertion of the femoral
arterial sheath, patients were treated with intravenous (IV)
heparin to maintain the activated clotting time (ACT)
$300 s (Hemachron method, International Technique,
Edison, New Jersey) throughout the procedure. After suc-
cessful intervention, patients were randomized to one of
three treatment groups: Group 1 received a prolonged
heparin infusion (13 U/kg/h, target ACT 160 to 190 s)
(11,12) for 12 to 24 h; vascular sheaths were removed when
the ACT was ,150 s, followed by discharge within 8 to
12 h. Group 2 did not receive heparin immediately after the
procedure. Vascular sheaths were removed when the ACT
was ,150 s, followed by reinstitution of heparin (13
U/kg/h, target ACT 160 to 190 s) (11,12) 4 h later for a
duration of 12 to 18 h; patients were then discharged from
the hospital. Group 3 did not receive any heparin after
intervention. Vascular sheaths were removed when the
ACT was ,150 s, followed by discharge within 8 to 12 h.
Vascular sheaths were removed by trained nurses, techni-
cians, or cardiology fellows, using manual or clamp com-
pression devices at the discretion of the operator. Hemo-
globin measurements were obtained in all patients 8 and
16 h after intervention.
End points. The primary end point was the combined
incidence of in-hospital bleeding and vascular events. Sec-
ondary end points included in-hospital ischemic events
(death, myocardial infarction [MI], coronary artery bypass
graft surgery [CABG], abrupt closure, repeat PTCA, or
“bailout” stent), stroke, length of hospital stay and cost. To
eliminate differences in the duration of hospitalization
before percutaneous revascularization, length of stay was
determined by the duration of hospitalization after revascu-
larization. The hospital cost was estimated by using the
1995 Medicare cost-to-charge ratio for each institution. To
evaluate the possibility that bleeding, vascular or ischemic
events might be missed by early hospital discharge, one-
month follow-up was recorded in all patients.
Definitions. Several definitions were used in this study:
major bleeding was defined as any bleeding requiring a
blood transfusion; major vascular events were defined as any
vascular repair, arteriovenous (AV) fistula, pseudoaneurysm,
femoral nerve injury or retroperitoneal hemorrhage; minor
bleeding was defined as a decrease in hemoglobin concen-
tration .3 g/dl, not requiring a blood transfusion; minor
vascular injury was defined as a femoral hematoma .6 cm,
not requiring transfusion or vascular repair. Major ischemic
complications were defined as chest pain with new electro-
cardiogram (ECG) changes, Q-wave and non-Q-wave
myocardial infarction, repeat PTCA, stent placement for
acute abrupt closure and CABG during the same hospital
stay. Myocardial infarction was defined as elevation in
creatine kinase (CK) greater than 23 normal, and elevation
of MB isoform.
Statistical analysis. Continuous variables were analyzed by
the Student t test, and categoric variables were analyzed by
the chi-square or Fisher exact test. Group comparisons were
performed by analysis of variance (ANOVA). Multivariate
analysis was performed using the Cox proportional hazards
regression model. Variables that proved to be significant on
univariate analysis or were believed to have important
prognostic value were entered into the multivariable model.
A p-value , 0.05 was considered statistically significant.
Sample size calculation was based on the assumption that
the incidence of bleeding and vascular complications for
patients receiving prolonged heparin was 15%; a total of
1,650 patients (550 patients per arm) would be required
(two-tailed t test) to demonstrate a 43% reduction to 8.5%
(90% power, alpha 5 0.05). Data were analyzed after entry
of 100 and 400 patients to ensure safety, and interim reports
were presented to the Human Investigations Committee.
Because of significant differences in outcome during interim
analysis, the study was prematurely terminated at the
recommendation of the Human Investigations Committee.
RESULTS
Patient population. The study population consisted of 414
patients. Patients in each group were similar with respect to
Abbreviations and Acronyms
ACT 5 activated clotting time
AV 5 arteriovenous
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
CK 5 creatinine kinase
ECG 5 electrocardiogram
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
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age, gender, height, weight, body surface area and prior
history of diabetes and peripheral vascular occlusive disease;
hypertension was more prevalent in Group 2 patients (Table
1). Clinical indications for revascularization included unsta-
ble angina in 69%, stable angina in 17% and postinfarction
angina in 14% of patients (Table 1). Patients in this study
represented a high-risk population, characterized by mul-
tivessel disease in nearly half of the patients (Table 2), and
by the need for preprocedural IV heparin infusion in more
than one-third of patients (Table 1).
Angiographic characteristics. Treatment groups were
similar regarding left ventricular ejection fraction, extent of
coronary artery disease and target vessel distribution (Table
2). The primary interventional device was PTCA alone in
88%; directional, mechanical or extractional atherectomy in
11%; and excimer laser angioplasty in 1%, using an average
arterial sheath of 8.1 6 0.5F.
Bleeding and vascular events. The combined incidence of
bleeding and vascular events was significantly higher in
patients who received prolonged heparin infusion compared
with those who did not receive additional heparin (Fig. 1):
21% in Group 1, 14% in Group 2 and 8% in Group 3 (p ,
0.01). The duration of postprocedural heparin infusion in
hours for Group 1 was 14.3 6 10.9 and for Group 2 was
12.9 6 5.8. Major bleeding and major vascular injury
occurred in 1% of patients, and there were no differences
between groups. However, minor bleeding complications
(defined as a decline in postprocedure hemoglobin .3 g/dl
p , 0.01) and minor vascular complications (femoral
hematoma; p 5 0.07) were more frequent in patients










Age (yrs) 62 6 11 62 6 10 62 6 11 61 6 11
Female (%) 136 (33) 50 (32) 41 (34) 45 (33)
BSA (m2) 1.9 6 0.3 1.9 6 0.3 1.9 6 0.3 1.9 6 0.3
Diabetes (%) 94 (23) 35 (22) 29 (24) 30 (20)
Peripheral vascular disease (%) 33 (8) 16 (10) 8 (7) 8 (6)
Hypertension (.140/90) (%)* 235 (57) 77 (49) 80 (67)* 78 (57)
Preprocedural heparin (%) 149 (36) 58 (37) 43 (36) 48 (35)
Angina type (%)
Stable 71 (17) 27 (17) 23 (19) 21 (15)
Unstable 284 (69) 112 (88) 83 (69) 89 (65)
Post-MI 59 (14) 18 (12) 14 (12) 27 (20)
BSA 5 body surface area; MI 5 myocardial infarction. Group 1 5 Continuous postprocedural heparin infusion; Group 2 5
sheaths removed, reinstitution of postprocedural heparin; Group 3 5 no heparin postprocedure.
*p , 0.05.










Ejection fraction (%) 53 6 4 52 6 4 54 6 4 52 6 4
Extent of CAD (%)
Single-vessel 224 (54) 87 (55) 60 (50) 77 (56)
Multivessel 190 (46) 70 (45) 60 (50) 60 (44)
Target vessel (%)
LM 1 (,1) 0 0 1 (,1)
LAD 180 (37) 72 (37) 45 (35) 63 (38)
LCX 159 (33) 61 (32) 44 (34) 54 (33)
RCA 147 (30) 60 (31) 40 (31) 47 (28)
Device (%)
PTCA 365 (88) 139 (89) 108 (90) 118 (86)
Atherectomy 46 (11) 17 (11) 11 (9) 18 (13)
Laser 3 (1) 1 (,1) 1 (1) 1 (1)
Arterial sheath (F) 8.1 6 0.5 8.1 6 0.5 8.1 6 0.5 8.1 6 0.5
LM 5 left main coronary artery; LAD 5 left anterior descending; LCX 5 left circumflex; RCA 5 right coronary artery;
PTCA 5 percutaneous transluminal coronary artery; F 5 French. Group 1 5 Continuous postprocedural heparin infusion;
Group 2 5 sheaths removed, reinstitution of postprocedural heparin; Group 3 5 no heparin postprocedure.
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receiving postprocedural heparin (Fig. 1). Minor bleeding
was also evaluated by the measurement of baseline and nadir
hemoglobin concentrations (Fig. 2): Although the prepro-
cedure hemoglobin concentration was similar for all three
groups, the nadir hemoglobin concentration was signifi-
cantly lower in patients receiving postprocedure heparin
infusion (p 5 0.002). Factors associated with combined
bleeding and vascular events were evaluated by univariate
and multivariate analysis (Table 3). Although body weight
,80 kg, body surface area ,1.94 cm2, age .62 years,
creatinine .1.2 mg/dl, vascular sheath time .8 h and the
use of heparin postprocedure were all associated with
combined bleeding and vascular events by univariate analy-
sis, only age .62 years and vascular sheath time .8 h were
independent predictors by multivariate analysis. The size of
the arterial sheath used was not associated with adverse
bleeding events in the univariate or multivariate model.
Ischemic complications. The overall incidence of major
ischemic complications was 2.2%, and there were no differ-
ences between groups. There were two patients in Group 1
who developed abrupt closure after the procedure; one was
treated conservatively and developed a Q-wave myocardial
infarction (MI), and the other developed non-Q-wave MI
after emergency repeat PTCA. One patient in Group 1 died
as a result of coronary perforation and cardiac tamponade,
not responding to pericardiocentesis. Three patients in
Group 2 had abrupt closure, including one who developed
non-Q-wave MI. All three patients were treated with
emergency percutaneous revascularization (PTCA alone in
one, stent placement in two). One other patient in Group 2
developed asymptomatic non-Q-wave MI and was treated
conservatively. Three patients in Group 3 developed isch-
emic complications: two patients developed MI and were
treated conservatively (Q-wave in one, non-Q-wave in one),
and one patient with multivessel disease underwent CABG
during the same hospitalization because of recurrent angina.
Length of hospital stay and cost. The postprocedure
length of hospital stay was significantly longer for patients
who received prolonged heparin infusion (Groups 1 and 2)
compared with Group 3 patients, who did not receive any
heparin (p 5 0.033). Patients with major bleeding and
vascular events (6.2 days vs. 1.3 days; p # 0.0001; 95% CI
[confidence interval] 4.01, 5.69), minor bleeding and vas-
cular events (1.7 days vs. 1.3 days; p 5 0.003; 95% CI 0.15,
0.74), major ischemic complications (2.2 days vs. 1.3 days;
p 5 #0.001; 95% CI 0.58, 1.29) and combined bleeding,
vascular, and ischemic events (1.9 days vs. 1.2 days; p #
0.001; 95% CI 0.43, 0.95) had significantly longer hospital
stay compared with patients without such complications
(Fig. 3). The total adjusted Medicare cost was significantly
higher in patients who received prolonged heparin infusion
(Fig. 4, p 5 0.0004; 95% CI 410.8, 1617.9). Because the
adjusted pharmacy cost, catheterization laboratory cost and
total cost per day were similar in all three groups, the
incremental cost in the groups receiving additional heparin
was largely attributed to the longer length of hospital stay.
Figure 1. The combined incidence of bleeding and vascular events
after successful percutaneous coronary intervention. Solid box 5
Group 1; striped box 5 Group 2; open box 5 Group 3. *p 5 0.01;
**p , 0.01; ***p 5 0.07.
Figure 2. Baseline (PRE) and postprocedural (NADIR) hemoglo-
bin concentrations in patients undergoing percutaneous coronary
intervention.
Table 3. Bleeding and Vascular Events of Patients Undergoing





Weight ,83 kg 0.009 0.253, 0.827
BSA ,1.94 cm2 0.02 0.289, 0.920
Age .62 years 0.001 1.505, 4.860
Creatinine .1.2 mg/dl 0.061 0.995, 12.394
Vascular sheath time .8 h 0.001 1.712, 6.291
Postprocedural heparin use 0.012 0.210, 0.836
Multivariate Characteristics
p Value Odds Ratio
Age .62 years 0.0002 2.605
Vascular sheath time .8 h 0.0012 3.171
BSA 5 body surface area.
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Follow-up. To evaluate the possibility that early hospital
discharge might have precluded identification of ischemic
and vascular complications, clinical follow-up was obtained
in all patients at one-month following discharge. Delayed
cardiac events occurred in 16 patients (4%), including death
(n 5 1, 0.2%), MI (n 5 2, 0.5%), repeat intervention on the
original lesion (n 5 8, 1.9%), and CABG (n 5 5, 1%).
There were eight patients in Group 1, five patients in Group
2, and three patients in Group 3 who had late cardiac events
(p 5 NS). Delayed major vascular events were identified in
three patients (1%), including vascular repair in two and
ultrasound compression of a pseudoaneurysm in one patient;
there were no differences between groups (two patients in
Group 2; one patient in Group 3).
DISCUSSION
Heparin during PTCA. Heparin is virtually always used
during PTCA to reduce the risk of abrupt closure (6–
8,13,14), but attempts to treat the patient, relieve coronary
ischemia and prevent vessel thrombosis may complicate
efforts to maintain hemostasis at the site of arterial access.
Although the activated clotting time (ACT) is commonly
used to monitor the “heparin-effect” (1,5) a standard ther-
apeutic ACT level has not been firmly established (16,17).
Although most interventional cardiologists utilize sufficient
heparin to maintain the ACT .300 s during the procedure
(1,9,15,18,19), the “average” heparin dose required to achieve
an ACT .300 s is dependent on several factors, including the
nature of the anginal syndrome (20), the influence of platelet
IIb/IIIa receptor antagonists (21), arterial versus venous sam-
ples (19,22,23), body weight (24) and the type of ACT device
(20,25). Although some studies suggest an inverse relationship
between ACT levels and ischemic complication (17,26),
higher ACT levels are also associated with more bleeding and
vascular complications. No patients received platelet glycopro-
tein receptor antagonists.
Heparin after PTCA and ischemic complications. In
contrast with the recognized value of intraprocedural hep-
arin to prevent ischemic complications, the need for post-
procedural heparin has not been confirmed in any subgroup
of patients with either stable or unstable angina (27).
Nevertheless, a recent national survey reported routine use
of postprocedural heparin in 70% of procedures (9). Fur-
thermore, because some studies suggest a relationship be-
tween dissection and acute abrupt closure (26), many
interventionalists, fearing a subclinical dissection, are reluc-
tant to discontinue heparin immediately after PTCA (1,28).
However, postprocedural heparin does not reduce abrupt
closure after successful PTCA (27), but does increase the
incidence of bleeding and vascular complications (3,10,28–
33). There are no data to suggest that routine postproce-
dural heparin decreases the risk of ischemic complications;
several studies suggest the safety of omitting postprocedural
heparin (10,27). The present study confirms and extends
these findings to patients with a variety of unstable ischemic
syndromes, including unstable angina and postinfarction
angina, who were routinely excluded from earlier studies
because of fear of ischemic complications.
Heparin and bleeding and vascular complications. In
contrast with the lack of influence of postprocedural heparin
on ischemic complications, this study and others (3,10,27–
33) demonstrate a relationship between postprocedural
heparin and bleeding and vascular complications. Use of
postprocedure heparin (Groups 1 and 2) was associated with
a significant drop in hemoglobin concentration in this study
and others (34). There are a number of potential explana-
tions for the association of prolonged heparin infusion with
bleeding and vascular complications. First, prolonged hep-
arinization exposes the patient to a sustained interval of
anticoagulation. Although “therapeutic” anticoagulation
may be well tolerated when mucosal and vascular integrity is
maintained, breach of vascular integrity may increase the
risk of iatrogenic bleeding and vascular complications.
Second, prolonged heparinization may be associated with
Figure 3. Relationship between length of hospital stay (LOS) and
bleeding, vascular, and ischemic events. *p # 0.0001; **p 5 0.003;
***p $ 0.001; ****p # 0.001.
Figure 4. Total adjusted Medicare cost after successful percutane-
ous coronary catheterization. p , 0.0001. Solid box 5 Group 1;
striped box 5 Group 2; open box 5 Group 3.
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delayed sheath removal (as in Group 1), which might
inhibit normal elasticity of the arterial wall to aid in closing
the entry site, leading to a “fixed opening.” Indeed, indwell-
ing vascular sheath duration .8 h was a strong independent
predictor of bleeding and vascular complications. Third, it is
difficult for most patients to remain supine and immobile for
prolonged periods, increasing the likelihood of excessive
patient movement, back pain and general discomfort; these
conditions can lead to tachycardia and hypertension, both of
which can potentiate groin complications.
Finally, other technical, patient (29,30,32,35,36) and
pharmacologic factors (36–38) may influence vascular com-
plications. Although some studies (32,33,38) show a rela-
tionship between vascular sheath size and vascular events,
others (29,30,39) (including the current study) did not.
Prevention of bleeding, vascular and ischemic complica-
tions. The most important way to reduce the risk of
bleeding and vascular complications is to avoid the use of
postprocedural heparin infusion after successful interven-
tion, and to remove the vascular sheaths when the ACT is
,150 s. When these principles are followed, the likelihood
of such complications will be determined primarily by
operator technique of vascular entry, groin compression and
patient factors such as low body weight and advanced age.
The role of vascular sealing devices is under investigation,
and there is potential for further reduction in complications
with these devices (40–42). In routine PTCA practice, the
most important factors in preventing ischemic complica-
tions are the administration of aspirin and heparin before
intervention. However, this study and others (10,27) indi-
cate that after successful intervention, postprocedural hep-
arin is not indicated to prevent ischemic complications, even
in high-risk patients. Although postprocedural heparin
infusions are often used after “suboptimal” PTCA, there are
no data to indicate that any level of systemic heparinization
is useful in preventing ischemic complications; further study
is needed. The efficacy of other potent antithrombin agents,
such as low molecular weight heparin, hirulog and hirudin
(43–45), may be similar to heparin, but it is uncertain
whether prolonged postprocedural use of these agents will
enhance safety. Finally, the availability of potent platelet
receptor antagonists has shown great promise in reducing
ischemic, bleeding and vascular complications, particularly if
postprocedural heparin is withheld (36,46–48).
Effects of postprocedural heparin on length of hospital
stay and cost. Bleeding and vascular complications are
important causes of patient morbidity after percutaneous
interventions. In this study and others (10), bleeding and
vascular complications were strongly associated with pro-
longed hospital stay and cost. If patients treated with
prolonged heparinization incur an incremental cost of
$1,000 per patient, it may be possible to have marked effect
on cost by eliminating the routine use of postprocedural
heparin: If 500,000 percutaneous interventions are per-
formed in the U.S. each year (including 250,000 PTCAs),
the incremental cost of postprocedural heparin is $250
million annually.
Study limitations. There are several potential study limi-
tations. First, this study was powered to detect differences in
bleeding and vascular complications, and was underpowered
to detect differences in low-frequency outcomes such as
death, myocardial infarction and CABG. It is possible that
recruitment of more patients may have allowed a more
powerful statement about ischemic complications. Second,
this study evaluated the use of heparin after “optimal”
intervention, and it was not designed to study another
important clinical issue, namely the use of heparin after
“suboptimal” intervention. Third, end points of this study
were clinical, not angiographic, outcomes. It is possible that
the patients enrolled represented a highly selected popula-
tion with superior angiographic results, and not the usual
“successful” PTCA. However, virtually all studies compar-
ing stenosis severity using visual estimates or quantitative
angiography suggest that postprocedural stenosis severity is
always underestimated by visual techniques. Thus, it is likely
that quantitative angiography would have revealed residual
stenosis .35%. Fourth, clinical follow-up was conducted
for one month after intervention to capture delayed complica-
tions. It is possible that later follow-up may have uncovered
additional complications, but we attempted to avoid the
dilemma of determining whether later ischemic complications
were due to the index procedure or to restenosis.
Conclusions. In summary, IV heparin infusion after suc-
cessful coronary interventions is associated with more minor
bleeding and vascular injury, and with prolonged length of
stay leading to increased hospital cost. Ischemic cardiac
events rarely occur after successful intervention, irrespective
of heparin use. Routine postprocedure heparin is not rec-
ommended, even in patients who present with unstable
ischemic syndromes.
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